KYMERA THERAPEUTICS, INC. Debt Securities, Available-for-sale, Sold at Par Value
KYMERA THERAPEUTICS, INC. (KYMR) reported Debt Securities, Available-for-sale, Sold at Par Value of $0 for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Notes
us-gaap:AvailableforsaleSecuritiesSoldAtPar · last filed 2023-11-02
- KYMERA THERAPEUTICS, INC. debt securities, available-for-sale, sold at par value for the quarter ending 2023-09-30 was $0.00.
- KYMERA THERAPEUTICS, INC. debt securities, available-for-sale, sold at par value for the quarter ending 2023-06-30 was $0.00.
- KYMERA THERAPEUTICS, INC. debt securities, available-for-sale, sold at par value for the quarter ending 2023-03-31 was $0.00.
- KYMERA THERAPEUTICS, INC. debt securities, available-for-sale, sold at par value for the quarter ending 2022-09-30 was $0.00.
- KYMERA THERAPEUTICS, INC. debt securities, available-for-sale, sold at par value for fiscal 2020 was $1.00.
- KYMERA THERAPEUTICS, INC. debt securities, available-for-sale, sold at par value for fiscal 2019 was $0.00.
| Period end | Debt Securities, Available-for-sale, Sold at Par Value 3 month | Debt Securities, Available-for-sale, Sold at Par Value 6 month | Debt Securities, Available-for-sale, Sold at Par Value 9 month | Debt Securities, Available-for-sale, Sold at Par Value 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | ||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | |||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2022-11-03 | $1.00 derived: sum of 4 quarters · filed 2022-05-03 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-06 | $0.00 10-Q · filed 2022-08-09 | $1.00 derived: sum of 3 quarters · filed 2022-05-03 | $1.00 derived: sum of 4 quarters · filed 2022-05-03 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-03 | $1.00 derived: sum of 2 quarters · filed 2022-05-03 | $1.00 derived: sum of 3 quarters · filed 2022-05-03 | $1.00 derived: sum of 4 quarters · filed 2022-05-03 |
| 2020-12-31 | $1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.00 derived: sum of 2 quarters · filed 2022-02-24 | $1.00 derived: sum of 3 quarters · filed 2022-02-24 | $1.00 10-K · filed 2022-02-24 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-06 | $0.00 10-Q · filed 2021-08-06 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |